SURF / Surface Oncology, Inc. (SURF) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Surface Oncology Inc. SURF, +1.37% stock is up 49% in premarket trades on Friday after the cancer drug company agreed to be acquired by Coherus BioSci more_horizontal

– SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC and HCC – more_horizontal

Surface Oncology has been a major drag for investors. There's no bad news, but there's no good news either. more_horizontal

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-genera more_horizontal

Surface Oncology, Inc. (SURF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepar more_horizontal

Surface Oncology, Inc. (SURF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepar more_horizontal

Surface Oncology, Inc. (SURF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepar more_horizontal

Cathie Wood stocks to watch right now. The post 7 Penny Stocks To Buy Based On Cathie Wood's ARK Invest Holdings appeared first on Penny Stocks to Buy more_horizontal